MEB and Swissmedic sign Memorandum of Understanding

The Medicines Evaluation Board (MEB) intends to intensify collaboration with its partner authority in Switzerland in the field of therapeutic product development and production. On 11 September 2018, MEB Chairman Ton de Boer and Executive Director Hugo Hurts signed a Memorandum of Understanding (MoU) with Swissmedic Director Raimund Bruhin.

The MoU provides a formal basis for stepping up collaboration on bilateral initiatives and the exchange of data. The two authorities are also involved in global multilateral initiatives such as the International Coalition of Medicines Regulatory Authorities (ICMRA) and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Closer cooperation between the MEB and Swissmedic therefore benefits both parties and will help them to accomplish their mission efficiently.

Given the constantly evolving regulatory environment and the ever-increasing global and complex nature of therapeutic product development and production, international collaboration is an important factor in meeting the growing challenges.

The MEB’s bilateral networking efforts focus primarily on therapeutic products agencies within and outside the EU with countries of strategic interest to the Netherlands.

MoU MEB and Swissmedic

From left to right: Swissmedic Director Raimund Bruhin with Ton de Boer (MEB Chairman) and Hugo Hurts (MEB Executive Director)

See also